491869-01-3

Upstream product

• 524774-86-5 4-(2-(3,4-bis-difluoromethoxy-phenyl)-2-{4-[2,2,2-trifluoro-1-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethoxy)-ethyl]-phenyl}-ethyl)-3-methyl-pyridine 
• 192767-12-7 (3,4-bis-difluoromethoxy-phenyl)-{4-[2,2,2-trifluoro-1-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethoxy)-ethyl]-phenyl}-methanol 
• 192767-13-8 [2-(1-{4-[(3,4-bis-difluoromethoxy-phenyl)-chloro-methyl]-phenyl}-2,2,2-trifluoro-1-trifluoromethyl-ethoxymethoxy)-ethyl]-trimethyl-silane 
• 192767-03-6 2-(4-bromophenyl)-2-[2-(trimethylsilyl)ethoxymethoxy]-1,1,1,3,3,3-hexafluoropropane 
• 59256-90-5 (3-methyl-pyridin-4-yl)-acetic acid methyl ester 
• 2402-72-4 2-(4-bromophenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 106-37-6 1.4-dibromobenzene 
• 583-58-4 3,4-Lutidin 

Relevant academic research and scientific papers

Substituted 4-(2,2-Diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters

A detailed SAR study directed toward the optimization of pharmacokinetic parameters for analogues of L-791,943 is reported. The introduction of a soft metabolic site on this structure permitted the identification of L-826,141 as a potent phosphodiesterase type 4 (PDE4) inhibitor that is well absorbed and that presents a shorter half-life than L-791,943 in a variety of animal species. The efficacy of L-826,141 is also demonstrated in different in vivo models.